Valvex 80/Valvex 160

Valsartan

In adults for essential HTN; clinically stable patients w/ symptomatic heart failure or asymptomatic left ventricular systolic dysfunction after a recent (12 hr-10 days) MI; symptomatic heart failure when ACE inhibitors cannot be used, or as add-on therapy to ACE inhibitors when β-blockers cannot be used. In childn & adolescents 6-18 yr for HTN.

HTN Adult Initially 80 mg once daily, may be increased to 160 mg once daily. Max: 320 mg once daily. Childn 6-18 yr weighing ≥35 kg 80 mg once daily, <35 kg Initially 40 mg once daily. Recent MI Initially 20 mg bid, started as early as 12 hr after MI. Dose should be titrated to 40 mg, 80 mg & 160 mg bid over the next few wk. Max daily dose: 160 mg bid. Heart failure Initially 40 mg bid, up-titrated to 80 & 160 mg bid at intervals of at least 2 wk. Max daily dose: 320 mg in divided doses.

May be taken with or without food.

Hypersensitivity. Severe hepatic impairment, biliary cirrhosis & cholestasis. Pregnancy (2nd & 3rd trimester).

Hyperkalemia. Risk of hypotension in Na &/or vol-depleted patients eg, receiving high doses of diuretics. Bilateral renal artery stenosis or stenosis to a solitary kidney; patients who have recently undergone kidney transplantation; aortic or mitral stenosis, or hypertrophic obstructive cardiomyopathy. Not to be used in patients w/ primary hyperaldosteronism. Patients w/ heart failure or post-MI. Concomitant use w/ K supplements, K-sparing diuretics, salt substitutes containing K, or other agents that may increase K levels (heparin). Not recommended to be used w/ ACE inhibitor; triple combination w/ an ACE inhibitor, β-blocker. Patients w/ CrCl <10 mL/min & undergoing dialysis. Discontinue immediately if angioedema occurs. Renal & mild to moderate hepatic impairment w/out cholestasis. Not to be initiated during pregnancy. Childn <6 yr. Not recommended for treatment of heart failure or recent MI in childn & adolescents <18 yr; paed patients w/ CrCl <30 mL/min & undergoing dialysis.

Dizziness, postural dizziness; hypotension, orthostatic hypotension; renal failure & impairment.

May increase lithium conc & toxicity. Increased serum K levels w/ K-sparing diuretics, K supplements, salt substitutes containing K. Attenuated antihypertensive effect w/ NSAIDs, selective COX-2 inhibitors, ASA >3 g/day), & non-selective NSAIDs. Increased risk of worsening of renal function & increase in serum K w/ NSAIDs. May increase serum K w/ other substances that inhibit the renin angiotensin aldosterone system.

Angiotensin II Antagonists

C09CA03 - valsartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx